San Francisco Bay Area biotech stories.
Friday, August 3, 2012
Crescendo tries to convince insurers to pay for its rheumatoid arthritis test
If you have rheumatoid arthritis, the course of your treatment can be determined this way: The doctor looks at, squeezes and evaluates 28 joints for swelling or tenderness then plugs that information into a formula that spits out a score
. So-called DAS28 tests are less than perfect, as you might guess. What's more, they are largely subjective and time consuming. It is difficult to figure out when to increase or discontinue a patient's use of the Genentech-developed RA drug Rituxan, for example, or to switch to another drug. DAS28 tests are used more for clinical trials than in clinical practice, but the leaders of Crescendo Biosciences Inc. are sure there's a better way for RA patients, physicians and the health-care system.
Share to Twitter
Share to Facebook
Share to Pinterest
Kleiner Perkins Caufield Byers
Mohr Davidow Ventures
Post a Comment
Post Comments (Atom)